SHANGHAI HENLIUS BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.5 HKD | +0.98% |
|
+11.34% | +18.71% |
| Apr. 26 | Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA | MT |
| Apr. 24 | Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 19,793 | 21,477 | 9,765 | 6,144 | 6,866 | 8,301 | - | - |
| Enterprise Value (EV) 1 | 18,101 | 22,196 | 9,765 | 6,144 | 6,866 | 8,301 | 8,301 | 8,301 |
| P/E ratio | -20.7 x | -21 x | -9.82 x | -8.83 x | 12.6 x | 13.7 x | 11.5 x | 9.94 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 218 x | 36.6 x | 5.8 x | 1.91 x | 1.27 x | 1.41 x | 1.29 x | 1.12 x |
| EV / Revenue | 218 x | 36.6 x | 5.8 x | 1.91 x | 1.27 x | 1.41 x | 1.29 x | 1.12 x |
| EV / EBITDA | -25.7 x | -25 x | -23.3 x | -19.8 x | 6.72 x | 7.73 x | 6.91 x | 5.92 x |
| EV / FCF | -14.5 x | -17.8 x | -9.38 x | - | 12 x | -692 x | 24.5 x | 9.73 x |
| FCF Yield | -6.89% | -5.62% | -10.7% | - | 8.36% | -0.14% | 4.08% | 10.3% |
| Price to Book | 4.53 x | 6.71 x | 4.25 x | 3.75 x | - | 2.94 x | 2.5 x | 2.06 x |
| Nbr of stocks (in thousands) | 543,495 | 543,495 | 543,495 | 543,495 | 543,495 | 543,495 | - | - |
| Reference price 2 | 36.42 | 39.52 | 17.97 | 11.30 | 12.63 | 15.27 | 15.27 | 15.27 |
| Announcement Date | 3/23/20 | 3/26/21 | 3/16/22 | 3/31/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 90.93 | 587.6 | 1,682 | 3,215 | 5,395 | 5,894 | 6,460 | 7,425 |
| EBITDA 1 | -768.7 | -857.8 | -420 | -310.6 | 1,021 | 1,074 | 1,202 | 1,402 |
| EBIT 1 | -851.2 | -993.6 | -620.2 | -323.8 | 662 | 759.5 | 856.7 | 1,087 |
| Operating Margin | -936.09% | -169.09% | -36.86% | -10.07% | 12.27% | 12.89% | 13.26% | 14.65% |
| Earnings before Tax (EBT) 1 | -874.8 | -993.5 | -956.7 | -693.9 | 569.6 | 676.5 | 808.9 | 964.5 |
| Net income 1 | -875.5 | -993.5 | -984.1 | -695.3 | 546 | 600.5 | 712.5 | 893.7 |
| Net margin | -962.8% | -169.09% | -58.49% | -21.63% | 10.12% | 10.19% | 11.03% | 12.04% |
| EPS 2 | -1.760 | -1.880 | -1.830 | -1.280 | 1.000 | 1.117 | 1.329 | 1.536 |
| Free Cash Flow 1 | -1,364 | -1,207 | -1,041 | - | 574.2 | -12 | 339 | 853 |
| FCF margin | -1,500.51% | -205.34% | -61.86% | - | 10.64% | -0.2% | 5.25% | 11.49% |
| FCF Conversion (EBITDA) | - | - | - | - | 56.23% | - | 28.2% | 60.85% |
| FCF Conversion (Net income) | - | - | - | - | 105.17% | - | 47.58% | 95.45% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/23/20 | 3/26/21 | 3/16/22 | 3/31/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | 719 | - | - | - | - | - | - |
| Net Cash position | 1,692 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.8386 x | - | - | - | - | - | - |
| Free Cash Flow 1 | -1,364 | -1,207 | -1,041 | - | 574 | -12 | 339 | 853 |
| ROE (net income / shareholders' equity) | -30.2% | -27.6% | -35.8% | -35.4% | 28.5% | 27.2% | 28.8% | 28.4% |
| ROA (Net income/ Total Assets) | - | -16.1% | - | - | - | 6.9% | 6.05% | 6.4% |
| Assets 1 | - | 6,169 | - | - | - | 8,703 | 11,777 | 13,964 |
| Book Value Per Share 2 | 8.050 | 5.890 | 4.230 | 3.010 | - | 5.200 | 6.100 | 7.400 |
| Cash Flow per Share | - | -1.230 | - | - | - | - | - | - |
| Capex 1 | 289 | 557 | 460 | 585 | 474 | 688 | 615 | 601 |
| Capex / Sales | 317.77% | 94.79% | 27.37% | 18.2% | 8.78% | 11.67% | 9.52% | 8.09% |
| Announcement Date | 3/23/20 | 3/26/21 | 3/16/22 | 3/31/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.27
CNY
Average target price
16.39
CNY
Spread / Average Target
+7.30%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +18.71% | 1.15B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 2696 Stock
- Financials Shanghai Henlius Biotech, Inc.
